Meet the Investors

2 & 3 April

Investors table

Thom Frielink | Associate, Curie Capital
Thom has over 6,5 years of consultancy experience in raising non-dilutive and dilutive funding for biopharmaceutical and medtech companies as advisor for Catalyze, Health-Holland and FFUND. In these years Thom was involved in raising over €85 million capital and has developed in-depth knowledge on a wide range of topics from ATMP and small molecule development to Medical Devices (class I, II and III) and in-vitro diagnostics. Next to his work at Curie Capital, Thom has completed an executive MBA at the Vlerick School of Business.

About Curie Capital

Curie Capital is a life science focused venture capital firm founded in 2018. It is a new and dynamic investment fund with a personal touch. Curie Capital is based in Amsterdam and invests in early stage companies with talented teams and exciting science and technology. The founding partners Mariette van der Velden and Han de Groot both have extensive experience in investing, entrepreneurship and managing companies across the full life cycle from startup to (public) exit. We invest in seed and series A stage Biotechnology, Pharmaceutical and Medical Technology companies, typically focused on therapeutics, diagnostics or class IIb and III medical devices.